After grappling with the initial Covid-19 frenzy, the diagnostic industry jumped back stronger to fulfil its role at the Test-Track-Treat strategy’s forefront. It has resulted in an unprecedented inflow of funds, inflating these companies’ valuations significantly. On the heels of this massively successful year, various private diagnostic service providers are eying an IPO in 2021. …